IUMC joins Alzheimer's drug trial

July 1995
Indianapolis Business Journal;7/10/95, Vol. 16 Issue 15, p22
Reports on the participation of the Indiana University Medical Center (IUMC) in the clinical trial of ADENA, a drug for treating Alzheimer's disease. Background on the clinical trials conducted at IUMC; Sponsorship of the trials by Sandoz Corp.; Common side effects seen for patients treated with ADENA; Findings of animal research for ADENA.


Related Articles

  • Problems Arising from the Generalising of Treatment Efficacy from Clinical Trials in Alzheimer's Disease: Mistaking Statistical Significance as Clinical Significance. Becker, R.; Markwell, S. // Clinical Drug Investigation;2000, Vol. 19 Issue 1, p33 

    Objective: To determine the accuracy a practicing physician could expect in assessments of drug response in Alzheimer's disease (AD). Methods: We used the Mini-Mental State Examination as a benchmark for the practising physician's ability to quantify cognitive capacity in Alzheimer's disease...

  • Nefiracetam: DM 9384, DZL 221, Translon.  // Drugs in R&D;2002, Vol. 3 Issue 3, p212 

    Adis Comments Nefiracetam [DM 9384, DZL 221] is a cyclic derivative of GABA that is under development with Daiichi Seiyaku for use in patients with dementia associated with Alzheimer's disease or secondary to cerebrovascular disorders. It is thought to act by normalising dysfunctional...

  • AXONYX Initiates Phase I Clinical Trial for Phenserine.  // Biotech Business;Feb2000, Vol. 13 Issue 2, p1 

    Presents information on the Phase I human clinical trial made by AXONYX Inc. for its Phenserine, an Alzheimer's disease drug.

  • Nerve inflammation halts trial for Alzheimer's drug. Check, Erika // Nature;1/31/2002, Vol. 415 Issue 6871, p462 

    Reports on the trials of immunotherapy drug for Alzheimer's disease as participants develop problems in the nervous system in the United States. Suspension of a patient trial of the drug; Elaboration of the investigation concerning the diagnosis on the inflammation; Tests conducted on the vaccine.

  • Noscira's Phase IIb Alzheimer's disease trial fails to meet endpoints.  // PharmaWatch: CNS;Dec2012, Vol. 11 Issue 12, p13 

    The article reports on the failure of Noscira's Phase IIb Alzheimer's disease trial to meet the primary cognitive endpoint and two of the secondary endpoints.

  • Trials in progress.  // Applied Clinical Trials;Apr2003, Vol. 12 Issue 4, p16 

    Reports on developments in clinical trials as of April 2003. Percentage of subjects with partial onset seizures who experienced clinical improvement when treated with the drug Keppra from UCB Pharma; Lowering of blood pressure in African-Americans by Cardizem in positive Phase 4 clinical...

  • Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics. Ritter, Aaron; Cummings, Jeffrey // Frontiers in Neurology;Aug2015, p1 

    With the demographic shift of the global population toward longer life expectancy, the number of people living with Alzheimer's disease (AD) has rapidly expanded and is projected to triple by the year 2050. Current treatments provide symptomatic relief but do not affect the underlying pathology...

  • You must remember this…. Pagán, Sylvia // New Scientist;8/3/2002, Vol. 175 Issue 2354, p14 

    Examines efficacy of antibiotic for treating Alzheimer's disease. Chemical reactions of the antibiotic; Demonstration of clinical trials; Accumulation of copper, iron and zinc in the brain.

  • A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease. Wilcock, Gordon; Howe, Ian; Coles, Hilary; Lilienfeld, Sean; Truyen, Luc; Zhu, Young; Bullock, Roger // Drugs & Aging;2003, Vol. 20 Issue 10, p777 

    Objective: To compare the long-term efficacy and safety of galantamine 24 mg/day and donepezil 10 mg/day in patients with Alzheimer's disease. Patients and Study Design: This was a rater-blinded, randomised, parallel-group multicentre study (18 outpatient clinics) in the UK. 182 patients (69...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics